Academia

An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Accountable care organizations (ACOs) with a major teaching hospital were associated with lower mortality, lower inpatient spending, lower emergency department utilization, and higher overall outpatient spending.

Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian cancer, which is a challenging patient population to treat, Angeles Alvarez Secord, MD, MHSc, gynecologic oncologist at Duke Health, said.

The rate of uninsurance in 2023 was 8.0%, a statistically insignificant change from the 7.9% uninsured rate in 2022.

Speakers at the 2024 World Conference on Lung Cancer discussed the considerations that must go into designing and performing clinical trials in the early-stage lung cancer space, ranging from selecting an end point to empowering participants.

Investigators noted that a formal independent validation cohort needs to be developed to realize the full potential of the human model.

Measurements on a standard phantom and a clinical data set of patients with Duchenne muscular dystrophy (DMD) were used to validate a novel robust reference frequency method approach, which outperformed typical imaging strategies.

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

A predictive tool considering disease duration, age at disease onset, age, and Expanded Disability Status Scale score estimated patients’ risk of transition to secondary progressive multiple sclerosis (MS).

A codesigned online nutrition program could potentially fill a need for reliable and evidence-based nutrition information for patients with multiple sclerosis (MS).

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

Tumor location, tumor size, and T stage associated with patients with rectal cancer who have inferior mesenteric artery lymph node metastases.

Trials of Duchenne muscular dystrophy (DMD) treatments targeting declining lung or upper limb function, which are typically limited to nonambulatory patients, could also include ambulatory patients, according to the study's findings

Artificial intelligence (AI) models have potential to help clinicians assess risk in patients with hepatocellular carcinoma (HCC) to inform disease management, a new study found.

Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.

A small trial by investigators at the National Cancer Institute holds promise to bring personalized cell therapy into the solid tumor arena, after more than a decade of success in blood cancers.

Both appendicular lean mass and fat mass index accounted for unique variance in motor function after controlling for age in patients with Duchenne muscular dystrophy (DMD).

Researchers from the University of Manchester sought to understand whether the season of administration of immunotherapy affected outcomes.

The addition of PD-1 inhibitors to first-line treatment with transarterial chemoembolization (TACE) plus lenvatinib for hepatocellular carcinoma (HCC).

Early tests show stem cells can be used to spark expression of a miniature version of the dystrophin protein.

Preexisting spinal damage and higher levels of inflammatory activity at baseline were linked with radiographic progression in axial spondyloarthritis treated with biologic disease-modifying antirheumatic drugs over 2 years regardless of treatment type.

High neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are associated with worse progression-free survival and 5-year overall survival in patients with ovarian cancer.

Slowing the loss of ambulation in patients with Duchenne muscular dystrophy (DMD) may also mitigate worsening disease burden and overall function, according to a pair of posters presented at ISPOR 2024.

Combining the anti-CD38 monoclonal antibody with a standard backbone triplet should be the new standard of care for newly diagnosed patients not eligible for transplant, said lead investigator Thierry Facon, MD.

A recent review highlighted several candidate biomarkers for diagnosing axial spondyloarthritis associated with inflammatory bowel disease in early phases.

This study identifies limited engagement with equity among academic medical centers as they develop governance processes for artificial intelligence (AI)/machine learning and predictive technologies.

This editorial discusses positions for academic medical centers to consider when designing and implementing artificial intelligence (AI) tools.